X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUVEN LIFE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUVEN LIFE ASTRAZENECA PHARMA/
SUVEN LIFE
 
P/E (TTM) x 155.7 17.2 902.9% View Chart
P/BV x 24.2 3.8 641.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SUVEN LIFE
Mar-18
ASTRAZENECA PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,285251 512.4%   
Low Rs634155 409.0%   
Sales per share (Unadj.) Rs189.649.1 385.9%  
Earnings per share (Unadj.) Rs-0.29.7 -2.1%  
Cash flow per share (Unadj.) Rs3.811.4 33.7%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs68.660.3 113.8%  
Shares outstanding (eoy) m25.00127.28 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.1 122.5%   
Avg P/E ratio x-4,712.720.9 -22,570.5%  
P/CF ratio (eoy) x249.617.8 1,401.3%  
Price / Book Value ratio x14.03.4 415.4%  
Dividend payout %015.4 0.0%   
Avg Mkt Cap Rs m23,98825,825 92.9%   
No. of employees `0001.61.1 145.4%   
Total wages/salary Rs m1,605613 261.9%   
Avg. sales/employee Rs Th3,040.25,832.6 52.1%   
Avg. wages/employee Rs Th1,029.2571.5 180.1%   
Avg. net profit/employee Rs Th-3.31,153.8 -0.3%   
INCOME DATA
Net Sales Rs m4,7406,253 75.8%  
Other income Rs m92233 39.6%   
Total revenues Rs m4,8326,485 74.5%   
Gross profit Rs m-1301,982 -6.5%  
Depreciation Rs m101213 47.5%   
Interest Rs m046 0.0%   
Profit before tax Rs m-1391,955 -7.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5718 0.7%   
Profit after tax Rs m-51,237 -0.4%  
Gross profit margin %-2.731.7 -8.6%  
Effective tax rate %-3.736.7 -10.0%   
Net profit margin %-0.119.8 -0.5%  
BALANCE SHEET DATA
Current assets Rs m2,7265,622 48.5%   
Current liabilities Rs m2,4351,168 208.5%   
Net working cap to sales %6.171.2 8.6%  
Current ratio x1.14.8 23.3%  
Inventory Days Days7481 90.6%  
Debtors Days Days4136 113.5%  
Net fixed assets Rs m1,0353,325 31.1%   
Share capital Rs m50127 39.3%   
"Free" reserves Rs m9427,547 12.5%   
Net worth Rs m1,7167,674 22.4%   
Long term debt Rs m014 0.0%   
Total assets Rs m4,1569,135 45.5%  
Interest coverage xNM43.2-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.7 166.6%   
Return on assets %-0.114.0 -0.9%  
Return on equity %-0.316.1 -1.8%  
Return on capital %026.0 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m3755,066 7.4%   
Fx outflow Rs m4702,001 23.5%   
Net fx Rs m-963,065 -3.1%   
CASH FLOW
From Operations Rs m-8699 -1.2%  
From Investments Rs m-146-6 2,388.5%  
From Financial Activity Rs m862-577 -149.4%  
Net Cashflow Rs m709116 609.2%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   12,856 37,287 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS